Concepts (234)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chagas Disease | 15 | 2024 | 320 | 3.730 |
Why?
|
| Trypanosoma cruzi | 13 | 2024 | 256 | 3.430 |
Why?
|
| Insect Vectors | 10 | 2024 | 113 | 2.200 |
Why?
|
| Triatoma | 6 | 2024 | 35 | 1.950 |
Why?
|
| Mosquito Vectors | 3 | 2025 | 34 | 1.770 |
Why?
|
| Texas | 24 | 2026 | 3686 | 1.520 |
Why?
|
| Rickettsia | 3 | 2025 | 17 | 1.250 |
Why?
|
| Tick Infestations | 2 | 2026 | 12 | 1.120 |
Why?
|
| Arboviruses | 2 | 2026 | 25 | 1.110 |
Why?
|
| Arbovirus Infections | 2 | 2026 | 30 | 1.100 |
Why?
|
| Culex | 2 | 2025 | 32 | 1.080 |
Why?
|
| Spotted Fever Group Rickettsiosis | 2 | 2025 | 5 | 1.030 |
Why?
|
| Superantigens | 2 | 2017 | 20 | 0.980 |
Why?
|
| Immunoglobulin M | 5 | 2024 | 210 | 0.970 |
Why?
|
| Felidae | 1 | 2026 | 2 | 0.960 |
Why?
|
| Flea Infestations | 1 | 2026 | 5 | 0.960 |
Why?
|
| Tick-Borne Diseases | 2 | 2025 | 16 | 0.960 |
Why?
|
| Ixodidae | 1 | 2026 | 6 | 0.960 |
Why?
|
| Siphonaptera | 1 | 2026 | 7 | 0.960 |
Why?
|
| Spatial Analysis | 2 | 2024 | 26 | 0.900 |
Why?
|
| Communicable Diseases, Emerging | 2 | 2025 | 71 | 0.890 |
Why?
|
| Rickettsia Infections | 1 | 2025 | 8 | 0.880 |
Why?
|
| Protozoan Infections | 1 | 2025 | 15 | 0.870 |
Why?
|
| Cysticercosis | 1 | 2024 | 21 | 0.860 |
Why?
|
| Culicidae | 1 | 2025 | 74 | 0.840 |
Why?
|
| Intestinal Diseases, Parasitic | 1 | 2025 | 43 | 0.840 |
Why?
|
| Neurocysticercosis | 1 | 2024 | 27 | 0.840 |
Why?
|
| Bacteria | 2 | 2026 | 521 | 0.830 |
Why?
|
| Helminthiasis | 1 | 2025 | 84 | 0.810 |
Why?
|
| Mexican Americans | 1 | 2024 | 162 | 0.790 |
Why?
|
| Antibodies, Catalytic | 2 | 2018 | 7 | 0.780 |
Why?
|
| Animals | 32 | 2026 | 33912 | 0.710 |
Why?
|
| Ehrlichiosis | 1 | 2021 | 10 | 0.690 |
Why?
|
| Antibodies, Protozoan | 2 | 2018 | 102 | 0.670 |
Why?
|
| Disease Reservoirs | 2 | 2026 | 36 | 0.610 |
Why?
|
| Deer | 1 | 2018 | 15 | 0.550 |
Why?
|
| Protozoan Proteins | 1 | 2018 | 128 | 0.520 |
Why?
|
| West Nile Fever | 4 | 2024 | 145 | 0.510 |
Why?
|
| Animals, Domestic | 1 | 2016 | 40 | 0.500 |
Why?
|
| Animals, Wild | 1 | 2016 | 32 | 0.490 |
Why?
|
| Cysteine | 1 | 2017 | 137 | 0.490 |
Why?
|
| Relapsing Fever | 3 | 2021 | 73 | 0.480 |
Why?
|
| Borrelia | 3 | 2021 | 84 | 0.470 |
Why?
|
| Seroepidemiologic Studies | 3 | 2025 | 158 | 0.470 |
Why?
|
| Leishmaniasis, Cutaneous | 2 | 2026 | 50 | 0.470 |
Why?
|
| Antigens, Protozoan | 1 | 2015 | 77 | 0.450 |
Why?
|
| West Nile virus | 3 | 2022 | 122 | 0.430 |
Why?
|
| Aedes | 2 | 2025 | 103 | 0.410 |
Why?
|
| Occupational Exposure | 1 | 2015 | 135 | 0.400 |
Why?
|
| Humans | 41 | 2026 | 131163 | 0.380 |
Why?
|
| Dengue Virus | 2 | 2024 | 135 | 0.350 |
Why?
|
| Dengue | 2 | 2024 | 125 | 0.350 |
Why?
|
| Public Health | 3 | 2026 | 269 | 0.350 |
Why?
|
| Disease Transmission, Infectious | 2 | 2026 | 71 | 0.330 |
Why?
|
| Ornithodoros | 2 | 2021 | 48 | 0.330 |
Why?
|
| Belize | 3 | 2025 | 26 | 0.310 |
Why?
|
| Fever | 4 | 2025 | 312 | 0.310 |
Why?
|
| Mexico | 3 | 2026 | 190 | 0.300 |
Why?
|
| Female | 19 | 2026 | 70963 | 0.300 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 919 | 0.280 |
Why?
|
| Male | 19 | 2026 | 64957 | 0.270 |
Why?
|
| Young Adult | 5 | 2025 | 10103 | 0.270 |
Why?
|
| Phylogeny | 5 | 2026 | 689 | 0.270 |
Why?
|
| Communicable Diseases | 2 | 2022 | 155 | 0.270 |
Why?
|
| Middle Aged | 9 | 2025 | 28601 | 0.260 |
Why?
|
| Cities | 2 | 2024 | 51 | 0.250 |
Why?
|
| Immunization | 2 | 2018 | 269 | 0.240 |
Why?
|
| Sympatry | 1 | 2026 | 4 | 0.240 |
Why?
|
| Nymph | 1 | 2026 | 14 | 0.240 |
Why?
|
| Leishmania mexicana | 1 | 2026 | 6 | 0.240 |
Why?
|
| Genome, Protozoan | 1 | 2026 | 25 | 0.240 |
Why?
|
| Rocky Mountain Spotted Fever | 1 | 2026 | 9 | 0.240 |
Why?
|
| Rheumatic Fever | 1 | 2026 | 20 | 0.240 |
Why?
|
| Cross-Sectional Studies | 2 | 2025 | 3829 | 0.230 |
Why?
|
| Ixodes | 1 | 2025 | 20 | 0.230 |
Why?
|
| Rheumatic Heart Disease | 1 | 2026 | 39 | 0.230 |
Why?
|
| Prevalence | 2 | 2025 | 2701 | 0.230 |
Why?
|
| Adolescent | 9 | 2026 | 20987 | 0.220 |
Why?
|
| Blastocystis | 1 | 2025 | 6 | 0.220 |
Why?
|
| Population Dynamics | 1 | 2025 | 30 | 0.220 |
Why?
|
| Poverty Areas | 1 | 2025 | 37 | 0.220 |
Why?
|
| B-Lymphocytes | 2 | 2018 | 509 | 0.220 |
Why?
|
| Population Density | 1 | 2024 | 31 | 0.220 |
Why?
|
| Strongyloides stercoralis | 1 | 2025 | 25 | 0.220 |
Why?
|
| Taenia solium | 1 | 2024 | 13 | 0.220 |
Why?
|
| Adult | 10 | 2025 | 31282 | 0.210 |
Why?
|
| Prealbumin | 1 | 2014 | 27 | 0.210 |
Why?
|
| Antibodies, Helminth | 1 | 2024 | 131 | 0.210 |
Why?
|
| RNA, Viral | 2 | 2024 | 497 | 0.210 |
Why?
|
| Climate Change | 1 | 2025 | 65 | 0.210 |
Why?
|
| Cat Diseases | 1 | 2023 | 15 | 0.200 |
Why?
|
| Amyloid | 1 | 2014 | 72 | 0.200 |
Why?
|
| Toxocariasis | 1 | 2023 | 29 | 0.200 |
Why?
|
| Seasons | 1 | 2025 | 335 | 0.190 |
Why?
|
| Models, Statistical | 1 | 2026 | 483 | 0.190 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2025 | 787 | 0.190 |
Why?
|
| Travel | 1 | 2024 | 117 | 0.190 |
Why?
|
| Risk Factors | 4 | 2026 | 11074 | 0.190 |
Why?
|
| Dog Diseases | 1 | 2023 | 58 | 0.190 |
Why?
|
| Proteolysis | 1 | 2014 | 200 | 0.190 |
Why?
|
| Antibodies, Bacterial | 1 | 2025 | 406 | 0.190 |
Why?
|
| Body Fluids | 2 | 2019 | 45 | 0.180 |
Why?
|
| Patient Selection | 1 | 2026 | 729 | 0.180 |
Why?
|
| Immunoglobulin G | 1 | 2025 | 786 | 0.180 |
Why?
|
| Meningitis, Aseptic | 1 | 2021 | 12 | 0.170 |
Why?
|
| Biodiversity | 1 | 2021 | 73 | 0.170 |
Why?
|
| Immunoglobulin A, Secretory | 1 | 2020 | 18 | 0.170 |
Why?
|
| Antibody Specificity | 2 | 2015 | 164 | 0.160 |
Why?
|
| Aged | 5 | 2025 | 21025 | 0.160 |
Why?
|
| Virus Diseases | 1 | 2022 | 285 | 0.150 |
Why?
|
| Residence Characteristics | 2 | 2021 | 295 | 0.140 |
Why?
|
| Polymerase Chain Reaction | 2 | 2019 | 1447 | 0.140 |
Why?
|
| Antibody Formation | 1 | 2018 | 227 | 0.130 |
Why?
|
| Mice | 4 | 2022 | 18301 | 0.130 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 915 | 0.130 |
Why?
|
| Hydrolysis | 1 | 2017 | 141 | 0.130 |
Why?
|
| DNA, Kinetoplast | 1 | 2017 | 4 | 0.130 |
Why?
|
| Arachnid Vectors | 1 | 2017 | 13 | 0.130 |
Why?
|
| Carrier State | 1 | 2017 | 80 | 0.120 |
Why?
|
| Methicillin Resistance | 1 | 2017 | 116 | 0.120 |
Why?
|
| Incidence | 2 | 2021 | 3360 | 0.120 |
Why?
|
| Chagas Cardiomyopathy | 1 | 2017 | 46 | 0.120 |
Why?
|
| Serine | 1 | 2017 | 161 | 0.120 |
Why?
|
| Protozoan Vaccines | 1 | 2017 | 101 | 0.120 |
Why?
|
| Food Chain | 1 | 2016 | 10 | 0.120 |
Why?
|
| Family Health | 1 | 2017 | 240 | 0.120 |
Why?
|
| Child, Preschool | 5 | 2026 | 15110 | 0.120 |
Why?
|
| Cardiomyopathies | 1 | 2021 | 514 | 0.120 |
Why?
|
| Mice, Inbred BALB C | 1 | 2018 | 978 | 0.120 |
Why?
|
| Protein Isoforms | 1 | 2017 | 423 | 0.120 |
Why?
|
| Sequence Alignment | 1 | 2017 | 582 | 0.120 |
Why?
|
| Calcium-Binding Proteins | 1 | 2017 | 325 | 0.120 |
Why?
|
| Zoonoses | 2 | 2026 | 52 | 0.110 |
Why?
|
| Genotype | 2 | 2019 | 2595 | 0.110 |
Why?
|
| Immunity, Innate | 1 | 2017 | 406 | 0.110 |
Why?
|
| Tuberculosis | 1 | 2020 | 550 | 0.110 |
Why?
|
| Child | 7 | 2026 | 26341 | 0.110 |
Why?
|
| Military Personnel | 1 | 2017 | 219 | 0.100 |
Why?
|
| Pandemics | 1 | 2021 | 1118 | 0.100 |
Why?
|
| Staphylococcus aureus | 1 | 2017 | 483 | 0.100 |
Why?
|
| Vaccination | 1 | 2018 | 1060 | 0.090 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2020 | 842 | 0.090 |
Why?
|
| Staphylococcal Infections | 1 | 2017 | 571 | 0.090 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 1319 | 0.090 |
Why?
|
| United States | 6 | 2026 | 12072 | 0.090 |
Why?
|
| Ecosystem | 2 | 2024 | 91 | 0.090 |
Why?
|
| Infant | 3 | 2026 | 13352 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2020 | 1459 | 0.080 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2021 | 377 | 0.070 |
Why?
|
| Saliva | 2 | 2020 | 125 | 0.070 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 6797 | 0.070 |
Why?
|
| Risk Assessment | 2 | 2016 | 3711 | 0.070 |
Why?
|
| Case-Control Studies | 1 | 2015 | 3359 | 0.070 |
Why?
|
| HIV Infections | 1 | 2020 | 2049 | 0.070 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 2323 | 0.060 |
Why?
|
| Epidemiological Monitoring | 2 | 2018 | 69 | 0.060 |
Why?
|
| Psychodidae | 1 | 2026 | 14 | 0.060 |
Why?
|
| Doxycycline | 1 | 2026 | 112 | 0.060 |
Why?
|
| Weather | 1 | 2024 | 14 | 0.050 |
Why?
|
| Florida | 1 | 2024 | 73 | 0.050 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 4066 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 2 | 2021 | 1692 | 0.050 |
Why?
|
| Nicaragua | 1 | 2024 | 30 | 0.050 |
Why?
|
| Serogroup | 1 | 2024 | 62 | 0.050 |
Why?
|
| Mutation | 1 | 2017 | 6099 | 0.050 |
Why?
|
| Cats | 1 | 2023 | 117 | 0.050 |
Why?
|
| Feeding Behavior | 2 | 2021 | 715 | 0.050 |
Why?
|
| Dominican Republic | 1 | 2023 | 15 | 0.050 |
Why?
|
| Substance P | 1 | 2022 | 31 | 0.050 |
Why?
|
| Dogs | 1 | 2023 | 613 | 0.050 |
Why?
|
| Panama | 1 | 2021 | 15 | 0.040 |
Why?
|
| Multilocus Sequence Typing | 1 | 2021 | 63 | 0.040 |
Why?
|
| Ticks | 1 | 2021 | 34 | 0.040 |
Why?
|
| Rodentia | 1 | 2021 | 50 | 0.040 |
Why?
|
| Haplotypes | 1 | 2022 | 519 | 0.040 |
Why?
|
| Discriminant Analysis | 1 | 2020 | 21 | 0.040 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2023 | 215 | 0.040 |
Why?
|
| Classification | 1 | 2020 | 18 | 0.040 |
Why?
|
| Philippines | 1 | 2020 | 22 | 0.040 |
Why?
|
| DNA Copy Number Variations | 1 | 2026 | 1029 | 0.040 |
Why?
|
| Plasmids | 1 | 2021 | 449 | 0.040 |
Why?
|
| Echocardiography | 1 | 2026 | 1125 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2021 | 481 | 0.040 |
Why?
|
| Dysbiosis | 1 | 2020 | 145 | 0.040 |
Why?
|
| Vero Cells | 1 | 2019 | 115 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2023 | 525 | 0.040 |
Why?
|
| Semen | 1 | 2019 | 84 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2019 | 5063 | 0.040 |
Why?
|
| Hospitals, Pediatric | 1 | 2023 | 808 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2020 | 297 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2022 | 1445 | 0.030 |
Why?
|
| Family Characteristics | 2 | 2017 | 93 | 0.030 |
Why?
|
| Arizona | 1 | 2017 | 25 | 0.030 |
Why?
|
| Triatominae | 1 | 2017 | 5 | 0.030 |
Why?
|
| Molecular Typing | 1 | 2017 | 32 | 0.030 |
Why?
|
| DNA, Satellite | 1 | 2017 | 15 | 0.030 |
Why?
|
| DNA, Intergenic | 1 | 2017 | 18 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2026 | 2833 | 0.030 |
Why?
|
| Feces | 1 | 2020 | 721 | 0.030 |
Why?
|
| Hospitalization | 1 | 2026 | 1950 | 0.030 |
Why?
|
| Molecular Epidemiology | 1 | 2017 | 139 | 0.030 |
Why?
|
| HIV-1 | 1 | 2020 | 490 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2017 | 110 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2023 | 1176 | 0.030 |
Why?
|
| Biomarkers | 1 | 2026 | 3385 | 0.030 |
Why?
|
| Bacterial Proteins | 1 | 2021 | 953 | 0.030 |
Why?
|
| Logistic Models | 1 | 2020 | 1797 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2019 | 1483 | 0.030 |
Why?
|
| Mammals | 1 | 2016 | 253 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1490 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2026 | 17753 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2026 | 2596 | 0.030 |
Why?
|
| Rural Population | 1 | 2016 | 276 | 0.020 |
Why?
|
| Aging | 1 | 2020 | 1242 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2017 | 970 | 0.020 |
Why?
|
| Brain | 1 | 2022 | 3175 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 4738 | 0.020 |
Why?
|
| Phenotype | 1 | 2019 | 4497 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2017 | 6459 | 0.010 |
Why?
|
| Hospitals, General | 1 | 1975 | 25 | 0.010 |
Why?
|
| Choice Behavior | 1 | 1975 | 148 | 0.010 |
Why?
|
| Decision Making | 1 | 1975 | 726 | 0.000 |
Why?
|
| Emergency Service, Hospital | 1 | 1975 | 1224 | 0.000 |
Why?
|
| Social Welfare | 1 | 1975 | 6 | 0.000 |
Why?
|
| Transportation of Patients | 1 | 1975 | 51 | 0.000 |
Why?
|
| Australia | 1 | 1975 | 173 | 0.000 |
Why?
|
| Family Practice | 1 | 1975 | 84 | 0.000 |
Why?
|
| Employment | 1 | 1975 | 74 | 0.000 |
Why?
|
| Income | 1 | 1975 | 138 | 0.000 |
Why?
|
| Insurance, Health | 1 | 1975 | 146 | 0.000 |
Why?
|
| Motivation | 1 | 1975 | 328 | 0.000 |
Why?
|
| Sex Factors | 1 | 1975 | 1356 | 0.000 |
Why?
|
| Age Factors | 1 | 1975 | 2825 | 0.000 |
Why?
|
| Time Factors | 1 | 1975 | 6196 | 0.000 |
Why?
|